Aligos Therapeutics, Inc.
No SEC Form 4 filings for $ALGS in the last 30 days.
Lake Street Capital began coverage of Aligos Therapeutics (NASDAQ:ALGS), assigning a “buy” rating and a $45.00 price target, according to MarketBeat Ratings. Other analysts cited mixed views, with Cantor “overweight” at $20 and Westpark “buy” at $48; MarketBeat shows a $38.50 consensus target. ALGS reported May 7 EPS of -$2.21 vs -$2.29 expected and revenue of $2.83M vs $0.25M.
Aligos Therapeutics said it presented at the EASL 2026 congress positive results for pevifoscorvir sodium in chronic hepatitis B. The company reported Phase 1 long-term follow-up showing reduced HBV cccDNA, and Phase 2 B-SUPREME data indicating lower HBV/HBV RNA and HBV levels below 3,000 IU/mL in some HBsAg+ patients after 96 weeks monotherapy.
Aligos Therapeutics reported its Q1 2026 business progress and financial results, highlighting the FDA's Fast Track Designation for its HBV drug, pevifoscorvir sodium, and a significant licensing deal with Amoytop for Greater China, including a $25M upfront payment. The company also announced an increase in Phase 2 clinical trial enrollment for pevifoscorvir sodium and the continuation of the B-SUPREME study after a positive interim analysis. Despite these clinical advancements and external funding, Aligos reported a net loss of $23.0 million for Q1 2026 and anticipates its current cash reserves will fund operations into Q4 2026.
